Halozyme TherapeuticsHALO +3.19%92 EBITDA Margin % is 58.29% as of Mar. 2026, which is 31% above its 10-year median of 44.42. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $90.32 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, Halozyme Therapeutics ranks better than 92.37% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Halozyme Therapeutics EBITDA Margin % Related Terms
Halozyme Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HALO vs IBRX, TECH, CORT: EBITDA Margin % Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (HALO) has a EBITDA Margin % of 58.29% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Halozyme Therapeutics and its competitors. This is 31% above median its historical median of 44.42. According to the industry distribution chart, Halozyme Therapeutics ranks #72 out of 944 companies in the Biotechnology industry, placing it in the top 7.6%.
Is Halozyme Therapeutics' EBITDA Margin % too high?
Halozyme Therapeutics' current EBITDA Margin % of 58.29% is 31% above median its 10-year median of 44.42. Based on the distribution chart, Halozyme Therapeutics ranks #72 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' EBITDA Margin % compare to IBRX and TECH?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #72 out of 944 companies for EBITDA Margin %. This places Halozyme Therapeutics in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current EBITDA Margin % is 58.29%, which is 31% above median its own 10-year median of 44.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.32, compared to a current price of $74.96 — trading 17% below its estimated fair value. The current EBITDA Margin % is 58.29%, which is 31% above median its 10-year median of 44.42. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current EBITDA Margin % is 58.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $74.96 is trading 17% below its estimated GF Value™ of $90.32.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
EBITDA Margin %: 58.29% (31% above median its 10-year median of 44.42)
GF Value™: $90.32 vs. price of $74.96 (17% below fair value)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score
Get the complete analysis for HALO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
